FOSUYFosun International Limited
The schedule
- Thu22Oct
Expected mid-quarter update on Fosun's ongoing non-core asset sales and balance sheet restructuring efforts.
- Mon25Jan
Fosun typically releases a preliminary trading update and profit alert ahead of its full-year results, providing insight into Q4 consumer and health segment performance.
- Tue30Mar
Full-year 2026 financial results, revealing the final audited impact of the corporate restructuring and core business turnaround.
Past
- Fri28Aug
Fosun International is scheduled to report H1 2026 earnings, following a highly publicized positive profit alert in late July that cited strong resilience in core industries.
- Sat15Aug
Actual outcome: Bull · $16.94 at outcome
FOSUY experienced a significant short-term price surge likely driven by a positive clinical trial readout, indicating promising results that exceeded market expectations. The move suggests strong data from a pivotal trial, potentially advancing the drug's development timeline and enhancing investor sentiment. The results may have signaled a favorable regulatory outlook or improved efficacy metrics. [Market retrospective · Short-Term (6–10 days)] Missed anticipation: +37.7% from 2026-07-31 to 2026-08-17 (~3.4σ vs typical 10d vol). Target evaluation date 2026-08-22 (not yet reached as of 2026-08-17). Confidence 95%. [Market retrospective · Short-Term (6–10 days)] Updated observation 2026-08-18: +37.7% from 2026-07-31 (~3.4σ). Target evaluation date 2026-08-22 (not yet reached as of 2026-08-18).
FOSUY experienced a significant short-term price surge likely driven by a positive clinical trial readout, indicating promising results that exceeded market expectations. The move suggests strong data from a pivotal trial, potentially advancing the drug's development timeline and enhancing investor sentiment. The results may have signaled a favorable regulatory outlook or improved efficacy metrics. [Market retrospective · Short-Term (6–10 days)] Missed anticipation: +37.7% from 2026-07-31 to 2026-08-17 (~3.4σ vs typical 10d vol). Target evaluation date 2026-08-22 (not yet reached as of 2026-08-17). Confidence 95%. [Market retrospective · Short-Term (6–10 days)] Updated observation 2026-08-18: +37.7% from 2026-07-31 (~3.4σ). Target evaluation date 2026-08-22 (not yet reached as of 2026-08-18).
